Abstract:Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS women often have increased central adiposity, insulin resistance, and renal injury. Hyperandrogenism is prevalent in PCOS women and is positively associated with metabolic dysfunction. Androgens bind to the androgen receptor (AR) to impart downstream transcriptional activity. Targeting the AR may alleviate PCOS complications, however the use of AR blockers is limited by their severe adverse effects in females thus safer alternative approaches are highly needed. ARV-110, a novel AR Proteolysis Targeting Chimera (PROTAC) degrader demonstrates high efficacy to prevent AR signaling in prostate cancer, however its efficacy in PCOS is unknown. Using a well-established hyperandrogenemic mouse model of PCOS, we aim to test the hypothesis that decreasing AR protein levels with ARV-110 will ameliorate androgen-mediated derangements in PCOS. Methods: Three-week old female mice (C57BL/6N) were implanted with Silastic tubes filled with the androgen dihydrotestosterone (DHT, 8mg, S.C., 90 days) or vehicle (n=6/grp). Four weeks post-DHT administration, mice were treated with ARV-110 (1 mg/kg/day, S.C.) for an additional 8 weeks. Body composition (EchoMRI) and the oral glucose tolerance test (OGTT) were assessed. Retroperitoneal fat (RPF) and kidney weights were measured by gravimetry. AR and extracellular matrix (ECM) remodeling marker MMP9 protein levels were assessed by Western blot, while the pro-fibrotic marker TGF-β was assessed by ELISA. Results: DHT mice showed significant (p<0.05) increases in body weight (27.3±0.6 vs 23.9±0.26 g), fat mass (4.2±0.6 vs 2.1±0.1 g), lean mass (21.6±0.2 vs 19.8±0.2 g), as well as RPF (244.4±37.4 vs 50.0±1.8 mg) and kidney weights (491.3±7.69 vs 303.1±5.5 mg) compared to controls. DHT increased fasting glucose (183.2±25.2 vs 141.5±9.9 mg/dL, p<0.05) and impaired OGTT (AUC:34557±6255 vs 23459±1896 mg.min/dL, p<0.05). ARV-110 treatment ameliorated all aforementioned DHT-mediated changes. On the molecular level, DHT mice had higher AR expression in RPF (1.5-fold) and kidney (2.5-fold), and higher MMP9 in both tissues (2- and 1.5-fold, respectively) indicating ECM remodeling. DHT had no significant effect on TGF-β in RPF but it upregulated TGF-β level in the kidney (2-fold, p<0.05). ARV-110 successfully decreased both RPF and renal AR protein levels by 70% in DHT mice compared to vehicle-treated DHT. Excitingly, while ARV-110 did not modulate RPF nor renal TGF-β levels, it completely abolished DHT-mediated MMP9 increase in both tissues. Conclusion and significance: Our findings suggest that DHT-mediated WAT expansion, kidney hypertrophy, and associated ECM remodeling are ameliorated by ARV-110 in DHT mice. These results highlight the pivotal role of AR in androgen-mediated and tissue-specific derangements common in PCOS. AR PROTACs could be a novel therapeutic approach to treat metabolic and renal dysfunction in PCOS. Supported by National Institute of General Medical Sciences of the National Institutes of Health grant P20GM121334 (L.L.Y.C. and D.G.R.), and American Heart Association Predoctoral Fellowship 903804 (A.M.H.) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Asprosin-neutralizing antibodies as a treatment for metabolic syndrome

Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects

Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis

Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor

Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice

Asprosin: its function as a novel endocrine factor in metabolic-related diseases

Asprosin aggravates atherosclerosis via regulating the phenotype transformation of vascular smooth muscle cells

Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity

The role of Asprosin in patients with dilated cardiomyopathy

Review of Asprosin as new Biomarker for diagnosis different Diseases

Multipotent Stromal Cells from Subcutaneous Adipose Tissue of Normal Weight and Obese Subjects: Modulation of Their Adipogenic Differentiation by Adenosine A1 Receptor Ligands

Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment

Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice

Targeting the immunoproteasome in hypothalamic neurons as a novel therapeutic strategy for high-fat diet-induced obesity and metabolic dysregulation

Asprosin: the potential player in combined double diabetes and hypothyroidism

Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases

Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice

Metabolomic and transcriptomic alterations in the colon of mice with metabolic syndrome in the absence of inflammation

Novel Androgen Receptor PROTAC Degrader ARV-110 Ameliorates White Adipose Tissue and Kidney Structural Derangements in a Mouse Model of Polycystic Ovary Syndrome

Genetic Evidence for GLP‐1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH

Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control